Aug. 15 at 5:43 PM
$TIVC The company's lead drug candidate, Entolimod™ for acute radiation syndrome, is a novel TLR5 agonist that has been granted Fast Track designation and is in late stage development. Low float no shares to borrow.
$GME $DWTX $CHWY.
$U.
